Warning letter
CGA Limited: warning letter of Dec 19, 2019
FDA warning letter 589028 · Center for Drug Evaluation and Research | CDER
Key facts
| Reference number | 589028 |
|---|---|
| Company | CGA Limited |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Dec 19, 2019 |
| Posted date | Jan 21, 2020 |
| Issuing office | Center for Drug Evaluation and Research | CDER |
| Product type | Drugs |
| CFR sections cited | 201.128, 211.34, 211.63, 330.1, 211.67(b), 211.165(a), 211.84(d)(1) |
| Inspection city | Laventille |
| Inspection start date | May 27, 2019 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: